Overview
SENTIS™ Cancer+ Discovery Testing
SENTIS™ Cancer+ Discovery Testing provides patients with one of the market’s most comprehensive and accurate NGS-based testing solutions for the identification of actionable somatic and germline mutations, and the discovery of novel variants with important functions in cancer.
The panel covers 816 cancer-related genes and interrogates the most common types of alteration (SNVs, indels, CNVs and fusions) in solid tumors. This provides comprehensive medication guidance on targeted therapy, chemotherapy and immunotherapy, as well as hereditary tumor risk assessment, to help patients find treatment options that may benefit them.
Applicable Clinical Scenarios
- Solid tumor in early and mid-stage, before neoadjuvant therapy
- Solid tumor in early and mid-stage, before adjuvant therapy
- Solid tumor in advanced stage, before first-line treatment
- Advanced solid tumor, to find the cause of drug resistance and adjust the treatment plan
What the Panel Covers
- 816 cancer-related genes
- SNVs, indels, CNVs and fusions
- Somatic and germline mutations
- Guidance on targeted therapy, chemotherapy and immunotherapy
- Hereditary tumor risk assessment